Skip to main content
Log in

Rapid Assessment of P-Glycoprotein Inhibition and Induction in Vitro

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. Using rhodamine123 (RH123) cell exclusion, 17 clinically used compounds were screened for their inhibitory effect on P-glycoprotein (P-gp), which was compared with the drugs' inhibitory activity against CYP3A4. The same assay was used to study induction of P-gp activity.

Methods. P-gp inhibition was assessed using RH123 accumulation into LS180V cells as well as Rh123 transport across Caco-2 monolayers. Inhibition of CYP3A4 was determined in human liver microsomes using triazolam-4-hydroxylation. Induction of P-gp expression and activity was measured using western blot analysis and RH123 accumulation into LS180V cells, respectively.

Results. The observed inhibition of RH123 cell exclusion ranged from little or no effect (digoxin, indinavir, fexofenadine) up to a nearly 10-fold increase in RH123 accumulation (ivermectin, terfenadine). No correlation between P-gp and CYP3A4 inhibition was observed. The rank order in P-gp inhibitory potency for terfenadine, verapamil, ritonavir, and indomethacin was identical in both LS180V and Caco-2 models. Ritonavir and St. John's wort extract showed a concentration-dependent P-gp induction, with good correlation between western blot analysis and RH123 accumulation.

Conclusions. The RH123 accumulation assay in LS180V cells can be used as a valuable screening tool to study both inhibition and induction of P-gp activity and expression. This assay has the potential to predict P-gp-mediated alterations in intestinal absorption of drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. I. Sugawara, I. Kataoka, Y. Morishita, H. Hamada, T. Tsuruo, S. Itoyama, and S. Mori. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. 48:1926-1929 (1988).

    Google Scholar 

  2. C. Cordon-Cardo, J. P. O'Brien, D. Casals, L. Rittman-Grauer, J. L. Biedler, M. R. Melamed, and J. R. Bertino. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 86:695-698 (1989).

    Google Scholar 

  3. V. Ling, N. Kartner, T. Sudo, L. Siminovitch, and J. R. Riordan. Multidrug-resistance phenotype in Chinese hamster ovary cells. Cancer Treat. Rep. 67:869-874 (1983).

    Google Scholar 

  4. M. D. Perloff, L. L. von Moltke, J. E. Marchand, and D. J. Greenblatt. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J. Pharm. Sci. 90:1829-1837 (2001).

    Google Scholar 

  5. A. R. Quesada, M. M. Barbacid, E. Mira, M. Aracil, and G. Marquez. Chemosensitization and drug accumulation assays as complementary methods for the screening of multidrug resistance reversal agents. Cancer Lett. 99:109-114 (1996).

    Google Scholar 

  6. J. G. Sarver, W. A. Klis, J. P. Byers, and P. W. Erhardt. Microplate screening of the differential effects of test agents on Hoechst 33342, rhodamine 123, and rhodamine 6G accumulation in breast cancer cells that overexpress P-glycoprotein. J. Biomol. Screen. 7:29-34 (2002).

    Google Scholar 

  7. J. S. Lee, K. Paull, M. Alvarez, C. Hose, A. Monks, M. Grever, A. T. Fojo, and S. E. Bates. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol. 46:627-638 (1994).

    Google Scholar 

  8. C. E. Herzog, M. Tsokos, S. E. Bates, and A. T. Fojo. Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J. Biol. Chem. 268:2946-2952 (1993).

    Google Scholar 

  9. E. StÖrmer, L. L. von Moltke, M. D. Perloff, and D. J. Greenblatt. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm. Res. 19:1038-1045 (2002).

    Google Scholar 

  10. M. D. Perloff, L. L. von Moltke, M. H. Court, T. Kotegawa, R. I. Shader, and D. J. Greenblatt. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J. Pharmacol. Exp. Ther. 292:618-628 (2000).

    Google Scholar 

  11. P. Artursson, K. Palm, and K. Luthman. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 22:67-84 (1996).

    Google Scholar 

  12. E. J. Wang, C. N. Casciano, R. P. Clement, and W. W. Johnson. In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab. Dispos. 28:522-528 (2000).

    Google Scholar 

  13. L. Profit, V. A. Eagling, and D. J. Back. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 13:1623-1627 (1999).

    Google Scholar 

  14. R. B. Kim, C. Wandel, B. Leake, M. Cvetkovic, M. F. Fromm, P. J. Dempsey, M. M. Roden, F. Belas, A. K. Chaudhary, D. M. Roden, A. J. Wood, and G. R. Wilkinson. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 16:408-414 (1999).

    Google Scholar 

  15. P. B. Watkins. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27:161-170 (1997).

    Google Scholar 

  16. L. L. von Moltke, D. J. Greenblatt, J. M. Grassi, B. W. Granda, S. X. Duan, S. M. Fogelman, J. P. Daily, J. S. Harmatz, and R. I. Shader. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J. Clin. Pharmacol. 38:106-111 (1998).

    Google Scholar 

  17. C. Wandel, R. B. Kim, S. Kajiji, P. Guengerich, G. R. Wilkinson, and A. J. Wood. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res. 59:3944-3948 (1999).

    Google Scholar 

  18. M. D. Perloff, L. L. von Moltke, E. StÖrmer, R. I. Shader, and D. J. Greenblatt. Saint John's wort: An in vitro analysis of P-glycoprotein induction due to extended exposure. Br. J. Pharmacol. 134:1601-1608 (2001).

    Google Scholar 

  19. E. G. Schuetz, W. T. Beck, and J. D. Schuetz. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-#x00AEulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49:311-318 (1996).

    Google Scholar 

  20. E. StÖrmer, L. L. von Moltke, M. D. Perloff, and D. J. Greenblatt. P-glycoprotein interactions of nefazodone and trazodone in cell culture. J. Clin. Pharmacol. 41:708-714 (2001).

    Google Scholar 

  21. D. Durr, B. Stieger, G. A. Kullak-Ublick, K. M. Rentsch, H. C. Steinert, P. J. Meier, and K. Fattinger. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 68:598-604 (2000).

    Google Scholar 

  22. B. Greiner, M. Eichelbaum, P. Fritz, H. P. Kreichgauer, O. von Richter, J. Zundler, and H. K. Kroemer. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104:147-153 (1999).

    Google Scholar 

  23. K. Westphal, A. Weinbrenner, M. Zschiesche, G. Franke, M. Knoke, R. Oertel, P. Fritz, O. von Richter, R. Warzok, T. Hachenberg, H. M. Kauffmann, D. Schrenk, B. Terhaag, H. K. Kroemer, and W. Siegmund. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 68:345-355 (2000).

    Google Scholar 

  24. M. Pinto, S. Robine-Leon, M. Appay, M. Kedinger, N. Triadou, E. Dussaulx, B. Lacroix, P. Simon-Assmann, K. Haffen, J. Fogh, and A. Zweibaum. Enterocyte-like differentiation and polarisation of the human colon carcinoma cell line Caco-2 in culture. Biol. Cell 47:323-330 (1983).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David J. Greenblatt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perloff, M.D., Störmer, E., von Moltke, L.L. et al. Rapid Assessment of P-Glycoprotein Inhibition and Induction in Vitro . Pharm Res 20, 1177–1183 (2003). https://doi.org/10.1023/A:1025092829696

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1025092829696

Navigation